Sanofi (SNY) Short-term Investments (2009 - 2021)
Sanofi (SNY) posted Short-term Investments of $12.5 million for Q4 2021, down 93.18% sequentially from $182.9 million in Q4 2020, and down 93.18% YoY from $182.9 million in Q4 2020.
Sanofi (SNY) Short-term Investments (2009 - 2021) Analysis & Trends
Sanofi has reported Short-term Investments for 13 years, with the latest figure at $12.5 million in Q4 2021.
- Quarterly Short-term Investments fell 93.18% year-over-year to $12.5 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $12.5 million (down 93.18% YoY) and the FY2021 annual result came in at $12.9 million, down 92.64% from the prior year.
- Short-term Investments slipped to $12.5 million in Q4 2021 per SNY's latest filing, from $182.9 million in the prior quarter.
- Over five years, Short-term Investments peaked at $227.1 million in Q4 2018 and troughed at $12.5 million in Q4 2021.
- A 5-year average of $132.0 million and a median of $147.0 million in 2019 frame the typical range for Short-term Investments.
- The sharpest annual moves came in 2017 and 2021: Short-term Investments jumped 170.86% in 2017, then slumped 93.18% in 2021.
- Over 5 years, Short-term Investments stood at $90.7 million in 2017, then soared by 150.53% to $227.1 million in 2018, then plunged by 35.28% to $147.0 million in 2019, then increased by 24.42% to $182.9 million in 2020, then slumped by 93.18% to $12.5 million in 2021.
- According to Business Quant data, Short-term Investments over the past three periods registered $12.5 million, $182.9 million, and $147.0 million for Q4 2021, Q4 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 12.47 Mn |
| Dec 31, 2020 | 182.90 Mn |
| Dec 31, 2019 | 146.99 Mn |
| Dec 31, 2018 | 227.14 Mn |
| Dec 31, 2017 | 90.66 Mn |
| Dec 31, 2016 | 33.47 Mn |
| Jun 30, 2016 | 146.88 Mn |
| Dec 31, 2015 | 14.25 Mn |
| Jun 30, 2015 | 249.76 Mn |
| Dec 31, 2014 | 272.46 Mn |
| Jun 30, 2014 | 93.29 Mn |
| Dec 31, 2013 | 251.80 Mn |
| Jun 30, 2013 | 107.07 Mn |
| Dec 31, 2012 | 230.85 Mn |
| Jun 30, 2012 | 425.31 Mn |
| Dec 31, 2011 | 233.15 Mn |
| Jun 30, 2011 | 165.43 Mn |
| Dec 31, 2010 | 69.26 Mn |
| Jun 30, 2010 | 230.75 Mn |
| Dec 31, 2009 | 409.06 Mn |